Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib Combination Therapy in KRAS-Mutated NSCLC
NCT07463677Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tunlametinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
tunlametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07463677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463677.